ArticleProbiotics and antimicrobial proteins2026
Lactiplantibacillus plantarum GUANKE Alleviates Intestinal Barrier Damage Caused by Influenza Infection in Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gut Microbiota and Probiotics in Influenza: A Narrative Review of Mechanisms and Emerging Evidence.Viruses · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Influenza, a highly transmissible acute respiratory illness caused by influenza viruses, is responsible for annual seasonal epidemics and poses a substantial global disease burden. While primarily recognized for its respiratory manifestations, influenza infection exhibits significant extrapulmonary effects, particularly through disrupting gut microbiota composition and compromising intestinal barrier integrity. This study investigates the protective efficacy of Lactiplantibacillus plantarum strain GUANKE against influenza-associated intestinal pathology in a murine model. Building on GUANKE's established safety profile and immunomodulatory capabilities, we employed a multi-faceted approach examining three key defense mechanisms: (1) maintenance of intestinal epithelial integrity, (2) preservation of chemical mucosal secretions, and (3) modulation of microbial homeostasis. Our findings establish crucial scientific evidence for probiotic-mediated protection of gastrointestinal function during influenza infection, potentially informing novel therapeutic strategies for virus-induced gut dysbiosis.
Indexed as
Identifiers
40668342What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.